Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have discovered sulfanilamide compounds acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and ciliopathy.